Avantor Investor Conference Presentation Deck

Exposed to attractive end markets Navantor™ BIOPHARMA + HSD growth rate ~55% -10% $7.5B -10% 2022E REVENUE -25% HEALTHCARE + MSD growth rate All growth rates represent expected long-term growth rates HSD = 7-9%; MSD = 4-6%; LSD = 1-3% 2022E data based on full year guidance as of Q3 earnings call. All other figures represent management estimates for FY 2022. EDUCATION & GOVERNMENT + LSD growth rate ADVANCED TECH & APPLIED MATERIALS + MSD growth rate 41st Annual J.P. Morgan Healthcare Conference 4

View entire presentation